PICKERING GRANT sold $1.2M of PCVX
PICKERING GRANT (CHIEF EXECUTIVE OFFICER) sold 22,461 shares of Vaxcyte, Inc. (PCVX) at an average of $52.50 ($52.50–$52.51, $1.18M total) across 2 trades on 2026-06-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The CEO’s open-market sale (under a 10b5-1 plan) is a sentiment datapoint but not a fundamental catalyst by itself.
Market read
Traders may monitor PCVX for any follow-on insider buying or additional disclosures, but this filing alone is unlikely to drive a major repricing.
What to watch
The article provides only the sale details; it does not include any concurrent buy activity, lock-up changes, or new company disclosures that would strengthen the signal.
Background
The article is an SEC Form 4 insider transaction disclosure for Vaxcyte, Inc. (PCVX).
Ticker impact
SEC Form 4 shows Vaxcyte CEO Grant sold 22,461 shares in open-market transactions at about $52.50 on 2026-06-18.
Likely limited near-term impact; any reaction should fade unless accompanied by other news.
The filing is a routine insider sale (10b5-1 pre-arranged) with no accompanying operational or guidance change disclosed in the text.
Market effects
Minimal; this is company-specific insider activity with no sector-wide regulatory/clinical signal in the text.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.
Key entities
- issuerVaxcyte, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderPICKERING GRANT
Chief Executive Officer and director who sold shares.
